Recent News

• 04.03.2025 - Trevi Therapeutics to Participate in Upcoming April Investor Conferences
• 03.18.2025 - Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates
• 03.11.2025 - Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025
• 03.10.2025 - Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
• 03.09.2025 - Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Recent Filings

• 03.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.21.2025 - 144 Report of proposed sale of securities
• 03.20.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 03.18.2025 - 8-K Current report
• 03.18.2025 - EX-99.1 EX-99.1
• 03.18.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.18.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.12.2025 - 4 Statement of changes in beneficial ownership of securities